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Abstract
Standard measures of effect, including the risk ratio, the odds ratio, and the
risk difference, are associated with a number of well-described shortcomings, and
no consensus exists about the conditions under which investigators should choose
one effect measure over another. In this paper, we introduce a new framework for
reasoning about choice of effect measure by linking two separate versions of the
risk ratio to a counterfactual causal model. In our approach, effects are defined in
terms of “counterfactual outcome state transition parameters”, that is, the propor-
tion of those individuals who would not have been a case by the end of follow-up
if untreated, who would have responded to treatment by becoming a case; and
the proportion of those individuals who would have become a case by the end of
follow-up if untreated who would have responded to treatment by not becoming
a case. Although counterfactual outcome state transition parameters are generally
not identified from the data without strong monotonicity assumptions, we show that
when they stay constant between populations, there are important implications for
model specification, meta-analysis, and research generalization.
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1. BACKGROUND
Causal effects often differ between groups of people. Consequently, investigators are often
required to reason carefully about which measures of effect, if any, can be expected to
remain homogeneous between different populations or different subgroups. Investigator
beliefs about effect homogeneity have important implications both for model specification,
and for the choice of summary metric in meta-analysis [1]. It is commonly believed that
the risk ratio is a more homogeneous effect measure than the risk difference, but recent
methodological discussion has questioned the evidence for the conventional wisdom [2, 3].
Approaches to effect homogeneity based on standard effect measures have several
noteworthy shortcomings, summarized for reference in Table 1:
1. Approaches that assume equality of the risk ratio or the risk difference may make
predictions outside the bounds of valid probabilities.
2. The odds ratio and the risk ratio have ”zero-constraints”: If the baseline risk in a
population is either 0 or 1, approaches based on assuming that the targeted odds
ratio is equal to the odds ratio in a referent population will necessarily result in
concluding that the exposure has no effect. [4]
3. If the risk difference, risk ratio, or odds ratio are equal across different populations,
then the proportion that responds to treatment in a given population is required to
be a function of that population’s baseline risk. [5]
4. The odds ratio is not collapsible; i.e the marginal value of the odds ratio may not be
equal to a weighted average of the stratum-specific odds ratios under any weighting
scheme, even in the absence of confounding and other forms of structural bias. [6]
5. The predictions of the risk ratio model are not symmetric to whether the parameter
is based on the probability of having the event, or the probability of not having the
event, i.e whether we ”count the living or the dead”. [7]
In addition to the five points discussed above, we note that no generally applicable
biological mechanism has been proposed that would guarantee the risk ratio, the risk
difference, or the odds ratio stays constant between different populations. For earlier
discussion of how biological mechanisms relate to the choice of effect measure, we point
the reader to Siemiatycki and Thomas (1981) and Thompson (1991) [8] and [9].
In this paper, we are interested in the effect of binary treatment A (e.g., a drug) on
binary outcome Y (e.g., a side effect) in two separate populations P = s and P = t.
In all examples, we have randomized trial evidence for the average causal effect of the
treatment in study population P = s , and wish to predict the effect of introducing
the treatment in the target population P = t, in which the drug is not available and
in which we can only collect observational data. Counterfactuals will be denoted using
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Table 1: Shortcomings of Effect Parameters
Risk Differ-
ence
Risk Ratio Odds Ratio COST
Parameters
Predicts invalid probabilities Yes Yes No No
Zero-constraints No Yes Yes No
Baseline risk dependence Yes Yes Yes No
Non-collapsibility No No Yes No
Asymmetry to outcome variable No Yes No No
superscripts. For example, Y a=0 is an indicator for whether an individual would have
experienced side effect Y if, possibly contrary to fact, she did not initiate treatment with
drug A. Because we have a randomized trial in study population s, the average baseline
risk Pr(Y a=0 = 1|P = s), and the average risk under treatment, Pr(Y a=1 = 1|P = s)
are identified from the data. Since treatment is not available in target population t,
the average baseline risk, Pr(Y a=0 = 1|P = t), is also identified from the data. Our
goal is to use this information, in combination with some plausible assumption about
effect homogeneity, to predict the average risk under treatment in the target population,
Pr(Y a=1 = 1|P = t).1
Briefly, we recall that VanderWeele (2012) [10] defined two separate types of effect het-
erogeneity: Effect modification in distribution (where the distributions of counterfactual
variables vary across populations) and effect modification in measure (where a particular
effect measure varies across populations). Here, we will propose a novel approach to effect
homogeneity based on a new class of non-identified effect parameters; and show how this
framework can sometimes be used to reason about homogeneity in terms of standard,
identifiable measures of effect such as the risk difference and the risk ratio. Specifically,
we will consider two risk ratios, which are equivalent to the two risk ratios considered by
1We note that considerations other than effect heterogeneity may also be relevant to the choice of effect
measure. In particular, while decision-making would benefit from information on both Pr(Y a=1|P = t)
and Pr(Y a=0|P = t) in order to weigh the costs and benefits of the intervention across different outcomes,
it may be sufficient to know the risk difference (RD), Pr(Y a=1−Y a=0|P = t), for example if the decision-
maker is neither risk-averse nor risk-seeking over the relevant outcome (that is, if their preferences can
be represented by a social welfare function which increases linearly with the number of averted incident
cases). This has been used as an argument in favor of measuring effects on the additive scale. Others
have argued that one should give preference to summary statistics which are readily understood by the
public, and that inverse measures of effect such as the number needed to treat (NNT) are better suited
for this purpose. The focus of the current paper is on situations where the investigators must present
a summary measure of an effect in a study population, possibly conditional on a set of effect modifiers,
for potential use across a range of different target populations. In such situations, generalizability is
prioritized over these other considerations, at least concerning the choice of initial effect measure.
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Deeks (2012) [4], and defined as follows:
RR(−) =
Pr(Y a=1 = 1)
Pr(Y a=0 = 1)
RR(+) =
1− Pr(Y a=1 = 1)
1− Pr(Y a=0 = 1)
=
Pr(Y a=1 = 0)
Pr(Y a=0 = 0)
This paper is organized as follows. In part 2, we describe a scenario to illustrate
the motivation for expanding upon existing effect parameters. In part 3, we introduce
counterfactual outcome state transition (COST) parameters, and propose a definition of
effect homogeneity based on these parameters. In part 4, we discuss the conditions under
which COST parameters are identified from the data, and the implications of violations
of these conditions. In part 5, we show that the COST parameters are not symmetric
to the coding of the exposure variable, and discuss the implications of this observation.
In part 6, we link COST parameters to substantive knowledge by providing examples of
biological processes that result in effect homogeneity. In part 7, we discuss the empirical
implications of our model. We conclude in part 8.
2. MOTIVATING EXAMPLE
Suppose a team of investigators have data from a randomized trial where the risk of a
particular side effect was 2% under no treatment and 3% under treatment. They wish
to predict the effect in a different target population, where the baseline risk of the side
effect is 10% (Table 2). For simplicity, we postulate that this treatment does not prevent
the outcome from occurring in any individual (“monotonic effect”); this assumption will
be discussed in detail later in the paper.
While discussing their data analysis plan, the first investigator postulates that the
standard risk ratio RR(−) is equal between these two populations. Under this assump-
tion, he estimates that 15% of the target population will experience the side effect under
treatment. However, a second investigator believes that RR(+), not RR(−), might be
equal between the two populations. Under this assumption, he estimates that 10.9% of
the target population will experience the side effect under treatment.
A third investigator notes that neither the first nor second investigator have substan-
tive arguments for choosing the RR(+) versus the RR(−). However, she realizes that the
group at risk of being adversely affected by treatment is the 90% of the target population
who were originally destined not to experience the side effect. She points out that the
first investigator’s assumption (i.e. that RR(−) was equal between the populations) re-
sults in a prediction that among people who are at risk of being adversely affected by the
4
Table 2: Predicted results using different effect measures
RR(−) RR(+) RD OR
Pr(Y a=0 = 1|P = s) 2% 2% 2% 2%
Pr(Y a=1 = 1|P = s) 3% 3% 3% 3%
Effect RR(−)=1.5 RR(+)=0.99RD=0.01 OR=1.515
Pr(Y a=0 = 1|P = t) 10% 10% 10% 10%
Predicted Pr(Y a=1 = 1|P = t) 15% 10.9% 11% 14.4%
treatment, the proportion who respond is much higher in population t than in population
s, simply because the baseline risk is higher.
Given this, the third investigator instead suggests assuming a specific probability is
constant across the populations: the probability that a person who was previously not
destined to experience the outcome, does not experience the outcome in response to
treatment. This probability can be computed in the trial as 97%
98%
≈ 99% and applied to
the 90% who were originally destined to be unaffected is the target population. In this
case, the third investigator’s approach results in the exact same estimate as the second
investigator’s approach: an estimated 10.9% of the target population will experience the
side effect under treatment.
Variations of the third investigator’s arguments have arisen independently multiple
times in the literature, dating back more than half a century [7, 4], but these recommen-
dations have rarely been translated into common practice. Throughout the rest of this
paper, we will formalize this line of reasoning in a counterfactual causal model, in order
to explore its scope, limits and implications.
3. DEFINITION OF THE COUNTERFACTUAL OUTCOME STATE TRANSITION
PARAMETERS
We define “counterfactual outcome state transition” (COST) parameters based on the
probability that a person who becomes a case if untreated remains a case if treated, and
by the probability that a person who does not become a case if untreated remains a
non-case if treated. We also offer interpretations of these quantities in terms of the four
deterministic response types [11] (Table 3). A list of parameters considered in this paper
is shown in Table 4.
Definition 1. G is defined as the probability of being a case if treated, among those who
would have been a case if untreated:
G = Pr(Y a=1 = 1|Y a=0 = 1)
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Definition 2. H is defined as the probability of not being a case if treated, among those
who would not have been a case if untreated:
H = Pr(Y a=1 = 0|Y a=0 = 0)
In a deterministic model, G can be interpreted as the proportion who are “Doomed”,
among those who are either “Doomed” or “Preventative” and H can be interpreted the
proportion who are “Immune”, among those who are either “Immune” or “Causal”. We
will refer to G and H as the COST parameters for introducing treatment. G and H
can be indexed for a specific population with subscripts (e.g., Gs is the parameter G in
population s). If the COST parameters for introducing treatment are equal between two
populations (i.e. if Gt = Gs and Ht = Hs,) this can equivalently be written as
Y a=1 ⊥ P |Y a=0
Similar conditions were considered in different contexts by Gechter (2015) [12] and by
Athey and Imbens (2006) [13]. In our setting of binary outcomes, this definition of
effect homogeneity addresses all previously discussed limitations of the standard effect
measures: The underlying parameters have no baseline risk dependence, do not produce
logically impossible results, are collapsible over arbitrary baseline covariates, and have no
zero constraints. Further, if the coding of the outcome is altered, the only consequence is
that the values of G and H are reversed. (See appendix 1)
4. IDENTIFICATION OF THE COUNTERFACTUAL OUTCOME STATE
TRANSITION PARAMETERS
Now that we have defined COST parameters, and described their motivation and attrac-
tiveness, we proceed to discuss how we can compute them in our studies. In an ideal
randomized trial, we can identify the standard effect measures (RR, RD) without fur-
ther assumptions beyond those expected to hold by design. Unfortunately, this is not
the case for COST parameters: COST parameters are generally not identifiable without
further assumptions. Therefore, even if we (somehow) knew that the parameters G and
H are equal between two populations, we may not be able to use this fact to predict
what happens when we introduce treatment in the target population. We next introduce
assumptions that lead to identifiability (Propositions 1, 4), and discuss scientific and clin-
ical implications when we are (Propositions 2, 5) and when we are not (Propositions 3,
6) willing to make those assumptions. The key identifiability assumption is monotonicity
[14, 15]: We say there is non-increasing monotonicity if individuals who do not get the
outcome if untreated, do not get the outcome if treated: Pr(Y a=1 = 1|Y a=0 = 0) = 0. In
other words, H = 1. Similarly, non-decreasing monotonicity occurs if individuals who get
the outcome if untreated also get the outcome if treated, in which case G = 1.
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Table 3: Counterfactual Response Types for Binary Outcomes
Type of indi-
vidual
Description of response type Potential outcomes
Type 1 No effect of treatment (Individual
Doomed to get the disease with
respect to exposure)
Y a=0 = 1, Y a=1 = 1
Type 2 Exposure Causative (Individual
susceptible to exposure)
Y a=0 = 0, Y a=1 = 1
Type 3 Exposure Preventative (Individ-
ual susceptible to exposure)
Y a=0 = 1, Y a=1 = 0
Type 4 No effect of treatment (Individual
Immune from disease with respect
to exposure)
Y a=0 = 0, Y a=1 = 0
Note that, under these definitions, it readily follows that Pr(Y a=0 = 1) =
Pr(Doomed) + Pr(Preventative) and that Pr(Y a=1 = 1)= Pr(Doomed) +
Pr(Causal).
Monotonicity is defined in the context of the specific exposure-outcome under consid-
eration, and its plausibility therefore needs to be evaluated on a case-by-case basis. This
means that within a trial, we may need to consider the plausibility of monotonocity for
each outcome of interest separately. For instance, the antiarrhythmic agent Amiodarone
can cause arrhythmia in some individuals and prevent it in others, and therefore does not
have monotonic effects for the arrhythmia outcome. However, if the outcome of interest is
a side effect such as pulmonary fibrosis, monotonicity may be a viable assumption because
the drug is unlikely to prevent any individual from getting pulmonary fibrosis. In general,
monotonicity could be a more reasonable approximation in situations where the outcome
is a side effect strongly associated with pharmacological treatment.
Proposition 1. If treatment monotonically reduces the incidence of event Y, then G is
identified from the data of a randomized trial, and is equal to the standard risk ratio,
RR(-).
Proposition 2. If the counterfactual outcome state transition parameters for introducing
treatment are equal between populations s and t, and if treatment monotonically reduces
the risk of the outcome, then RR(−) in the target population is equal to RR(−) in the
study population.
Proposition 3. If the counterfactual outcome state transition parameters for introducing
treatment are equal between populations s and t, and if treatment reduces the incidence
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Table 4: List of parameters
Parameter Definition Key conditions for
identification
Identifying expression
RR(−) Pr(Y
a=1=1)
Pr(Y a=0=1) No confounding
Pr(Y =1|A=1)
Pr(Y =1|A=0)
RR(+) Pr(Y
a=1=0)
Pr(Y a=0=0)
No confounding Pr(Y =0|A=1)Pr(Y =0|A=0)
G Pr(Y a=1 = 1|Y a=0 = 1) No confounding
and non-increasing
monotonicity
RR(−)
H Pr(Y a=1 = 0|Y a=0 = 0) No confounding
and non-decreasing
monotonicity
RR(+)
I Pr(Y a=0 = 1|Y a=1 = 1) No confounding
and non-decreasing
monotonicity
1
RR(−)
J Pr(Y a=0 = 0|Y a=1 = 0) No confounding
and non-increasing
monotonicity
1
RR(+)
All parameters shown above are defined separately in populations s and t. When-
ever we need to clarify the population in which the parameter is defined, subscripts
are used (e.g., RR(−)s).
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of Y but not monotonically, then RR(−) in the study population is a biased estimate of
RR(−) in the target population.2 If the baseline risk in the target population is lower
than in the study population, then the true risk under treatment in the target population
is higher than what would be predicted by assuming RR(−)s = RR(−)t, whereas the
opposite holds if the baseline risk is higher in the target population. The magnitude of
the bias is a function of the extent of non-monotonicity, and of the ratio of baseline risk
between the two populations (see appendix 2).
The following three propositions are exactly symmetric to the preceding results, but
apply to situations where exposure increases the risk of the outcome (i.e., monotonicity
holds in the other direction). In such situations, we identify H instead of G:
Proposition 4. If treatment monotonically increases the incidence of event Y , then H
is identified from the data of a randomized trial, and is equal to the recoded risk ratio
RR(+)
Proposition 5. If the counterfactual outcome state transition parameters for introducing
treatment are equal between populations s and t, and if treatment monotonically increases
the risk of the outcome, then RR(+) in the study population is equal to RR(+) in the
target population.
Proposition 6. If the counterfactual outcome state transition parameters for introducing
treatment are equal between populations s and t, and if treatment increases the incidence
of Y but not monotonically, then RR(+) in the study population is a biased estimate of
RR(+) in the target population.
Proofs of propositions (1-6) are provided in Appendix 2.
5. ASYMMETRY TO THE CODING OF THE EXPOSURE VARIABLE
So far, we have focused on problems – and resolutions to some problems – related to how
the investigator encodes the outcome variable in the database. However, COST parame-
ters are not invariant to the coding of the exposure variable. To illustrate, reconsider the
2If there is substantial non-monotonicity or if the baseline risks differ substantially between the pop-
ulations, the bias term gets very large, resulting in highly biased estimates which may even be on the
wrong side of 1. For example, if G is 0.05 and H is 0.99 in both populations, and the baseline risk is 0.005
in the study population but 0.05 in the target population, then the true risk ratio in the target population
is 0.24, but the risk ratio in the study population is 2.05. We therefore caution against using RR(−)s as
an approximation of RR(−)t unless it is plausible, in both populations, to expect ”near-monotonicity”,
defined as G×Pr(Y a=0 = 1) ≫ (1 − H) × (Pr(Y a=0 = 0). This condition, which ensures that G is
approximately equal to RR(−), will be met if the prevalence of the ”doomed” response type is much
higher than the prevalence of the ”causative” response type. In the setting of a randomized trial, this
might be a reasonable approximation if there is reason to believe that a great majority of the events in
the treatment arm would have occurred even in the absence of treatment.
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trial where the risk under treatment was 3% and the risk under no treatment was 2%. If
we reverse the coding of the exposure variable, we notice that the new exposure variable
in fact reduces the risk of the outcome, meaning that a naive application of our approach
would suggest using the standard (but now inverted) risk ratio 1
RR(−)
to estimate the
probability of being unaffected by treatment. However, there is a subtle but important
distinction from the earlier approach: by changing the definition of exposure, we have also
changed the meaning of the parameter so that it is now defined as the probability of be-
ing unaffected by treatment among those who would have become cases under treatment,
rather than among those who would have become cases under no treatment. This can be
conceptualized as the effect of removing treatment from a fully treated population.
We will refer to the COST parameters associated with removing treatment as I and
J . The choice of coding of the exposure variable is then equivalent to choosing whether
to model equality of effect based on the parameters G and H , or based on the parameters
I and J . For notational simplicity, we will continue to use the original coding of the
exposure variable, and instead frame the question in terms of whether an investigator
should define equality of effects based on the parameters G and H , or the parameters I
and J .
Definition 3. I is defined as the probability of being a case if untreated, among those
who would have been a case if treated:
I = Pr(Y a=0 = 1|Y a=1 = 1)
Definition 4. J is defined as the probability of not being a case if untreated, among
those who would not have been a case if treated:
J = Pr(Y a=0 = 0|Y a=1 = 0)
In a deterministic model, I can be interpreted as the proportion who are “Doomed”,
among those who are either “Doomed” or “Causal”, and J can be interpreted the pro-
portion who are “Immune”, among those who are either “Immune” or “Preventative”. If
the COST parameters for removing treatment are equal between two populations (i.e. if
It = Is and Jt = Js,) this can equivalently be written as Y
a=0 ⊥ P |Y a=1. With these
definitions, results exactly analogous to propositions 1 through 6 can be derived for I and
J .
As implied earlier in this section, one can construct examples to show that equality of
COST parameters for introducing treatment does not imply equality of COST parameters
removing treatment. In fact, if the baseline risks differ, then the two homogeneity condi-
tions rarely hold simultaneously (an obvious exception to this would be under the sharp
causal null hypothesis). This observation arguably presents a major conceptual challenge
to the claim that our definition captures the intuitive idea of “equal effects”: to make our
inferences invariant to the coding of the outcome, we have made them dependent on the
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coding of the exposure. However, in the next section, we show that, with some background
knowledge about biological mechanisms, it is possible to reason about whether the COST
parameters for introducing treatment are more likely to be homogeneous than the COST
parameters for removing treatment. In particular, we show that it is possible to provide
models for the data-generating process that guarantee equality of the COST parameters
for introducing treatment, equality of the COST parameters for removing treatment, or
neither.
6. BIOLOGICAL KNOWLEDGE AND EQUALITY OF TREATMENT EFFECTS
While it is usually not possible to reason a priori about whether the risk difference or odds
ratio are equal between populations, we now provide a simple example to show that it
is sometimes possible to reason based on biological knowledge about whether the COST
parameters are equal between populations. This is intended only as a proof-of-concept,
and the example is purposefully oversimplified in order to illustrate the principles. An
outline of a formal treatment of these ideas is provided in Appendix 3.
Consider a team of investigators who are interested in the effect of antibiotic treatment
on mortality in patients with a specific bacterial infection. Since this antibiotic is known
to reduce mortality, the investigators need to decide whether to report RR(−) as an
approximation of G, or alternatively RR(+) as an approximation of 1
J
. In order to ensure
external validity, this choice will be determined by their beliefs about which parameter is
most likely to be constant across populations.
The investigators believe that the response to this antibiotic is completely determined
by an unmeasured bacterial gene, such that only those who are infected with a bacterial
strain with this gene respond to treatment. The prevalence of this bacterial gene is equal
between populations, because the populations share the same bacterial ecosystem. If,
as seems likely, the investigators further believe that the gene for susceptibility reduces
mortality in the presence of antibiotics, but has no effect in the absence of antibiotics, they
will conclude that G may be equal between populations. If, on the other hand, they had
concluded that the gene for susceptibility causes mortality in the absence of antibiotics
but has no effect in the presence of antibiotics, they would instead expect equality of J
across populations.
For many antimicrobial therapies, the microbial genes that determine antibiotic sus-
ceptibility generally have functions that are perhaps better approximated by the first
approach, and therefore motivates the choice to model the data as if G is equal between
the populations. In other situations, in the presence of different subject matter knowl-
edge, similar logic could be used to reach different conclusions. One example of this
occurs in pharmacological applications involving adverse reactions to drugs, where it may
be reasonable to use the parameter H if the determinants of susceptibility are equally dis-
tributed between populations, under certain assumptions about how those determinants
interact with the drug. In many realistic applications, it may be more plausible that the
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COST parameters for introducing treatment are equal than the corresponding parameters
for removing treatment, but this is by no means universal: for example, if some humans
had retained our ancestors’ ability to synthesize Vitamin C endogenously, then the effect
of fresh fruit on scurvy might be better modeled based on the parameter J .
In most settings, the particular function of the attribute that determines treatment
susceptibility will not be known. In such situations, it is necessary to reason on theoretical
grounds about which model is a better approximation of reality. One possible approach to
determine whether either type of effect equality is biologically plausible would be to con-
sider how an attribute or gene with the necessary function avoided either reaching fixation
or being selected out of existence. For example, a genotype that causes the outcome in the
presence of exposure will very likely go extinct in a population where everyone is exposed,
but may survive in a proportion of a population where everyone is generally unexposed.
This equilibrium may be equal between different groups of people (for example, equal
between men and women in the same gene pool). Therefore, if treatment was unavailable
in recent evolutionary history, the COST parameters for introducing introducing treat-
ment may be more likely to be equal than the COST parameters for removing treatment.
Similarly, an attribute that prevents the outcome in the absence of exposure will quickly
reach fixation if everyone is unexposed, but its absence may survive in a small, stable
fraction of the population if everyone is exposed. Therefore, if everyone were exposed in
recent evolutionary history, the COST parameters for removing treatment may be more
likely to be equal than the COST parameters for introducing treatment. Thus, this line
of reasoning may provide an additional viable argument for choosing the index level of
the exposure variable based on the value which it took by default in recent evolutionary
history.
7. TESTING FOR HETEROGENEITY
If we believe that the COST parameters for introducing treatment are equal across pop-
ulations, an empirical implication is that meta-analysis based on RR(−) will be less
heterogeneous for exposures which monotonically reduce the incidence of the outcome,
whereas meta-analysis based on RR(+) will be less heterogeneous for exposures which
monotonically increase the incidence of the outcome.
However, this observation is complicated by an additional asymmetry associated with
the ratio scale: If the outcome is rare (which is usually the case), Pr(Y a=1 = 0) and
Pr(Y a=0 = 0) will both be close to 1, and RR(+) will therefore also be close to 1, even
if treatment has a substantial effect. This results in a compression of the RR(+) scale,
such that when heterogeneity is measured in terms of the absolute differences between
effect sizes, clinically meaningful heterogeneity between populations will only be apparent
at the second or even third decimal space. In contrast, heterogeneity on the RR(−)
scale generally manifests itself at the first decimal. Therefore, any attempt to measure
heterogeneity based on the absolute difference between each study’s estimate and the
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overall meta-analytic estimate will result in higher values for RR(−) than RR(+) for rare
outcomes, for reasons that arguably say more about the mathematical differences between
the scales than about their relative usefulness for summarizing effect sizes.
One option may be to quantify each study’s deviation from the common effect in terms
of the lowest possible proportion of individuals whose outcome variable must be “switched”
in order for the effect estimate in the study to equal the overall meta-analytic estimate.
Another potential approach to this problem is to use the Risk Difference (RD) in place of
RR(+) for exposures which increase the incidence of Y . In Appendix 4, we show that if the
outcome is rare, effect homogeneity on the RR(+) scale implies near-homogeneity on the
risk difference scale. This approach is consistent with previous suggestions to consider the
“relative benefits and absolute harms” [16] of medical interventions. Investigators using
this approach must further keep in mind the potential differences in power between tests
for homogeneity on the additive and multiplicative scales. [2]
8. CONCLUSION
We have proposed a new approach to considering effect equality across populations, which
avoids several well-established shortcomings of definitions based on standard effect mea-
sures. Our approach distinguishes equality of the effect of introducing the treatment to
a fully untreated population from equality of the effect of removing the treatment from a
fully treated population; and therefore requires investigators to reason carefully about the
distinction between the two homogeneity conditions. Further, we provided examples of
biological models that correspond to each form of effect equality. While the utility of our
approach is limited to the restricted range of applications where these biological models
are a reasonable approximation of reality, we believe such applications could occur with
some frequency when studying the effectiveness and safety of pharmaceuticals.
If investigators are willing to assume that the COST parameters for introducing treat-
ment are equal between populations, it follows that the standard risk ratio RR(−) should
be used for exposures which monotonically reduce the incidence of the outcome, and that
the recoded risk ratio RR(+) should be used for exposures which monotonically increase
the risk of the outcome. Thus, the risk ratio will generally be constrained between 0 and 1.
If the outcome is rare, RD may be used in the place of RR(+) for exposures that increase
the incidence of the outcome. If the effect of exposure is not monotonic, the investigator
may still choose the risk ratio model based on whether treatment increases or decreases
the risk on average; in such situations, the extent of bias will be small if the extent of
non-monotonicity is small, or if the populations have comparable baseline risks. This
approximation is highly sensitive to violations of these conditions, and if there is reason
to suspect substantial non-monotonicity, identification is not feasible and investigators
may consider using an alternative approach to effect homogeneity [[17, 18]].
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APPENDIX 1: PROPERTIES OF COST PARAMETERS
Valid predictions: The COST parameter approach results in predictions for Pr(Y a=1 =
1|P = t) that are valid probabilities, i.e. that are contained in the interval [0,1]. The
predictions are generally of the form Pˆr(Y a=1 = 1|P = t) = Pr(Y a=0 = 1|P = t) × G +
(1 − Pr(Y a=0 = 1|P = t)) × (1−H). In other words, Pˆr(Y a=1 = 1|P = t) is a weighted
average of G and 1-H . Since both G and 1-H are contained in [0,1], the prediction is also
in this interval.
No Zero-Constraints: Here, we show that for any baseline risk in the target population
Pr(Y a=0 = 1|P = t), there exist possible values of the COST parameters such that
Pr(Y a=1 = 1|P = t) 6=Pr(Y a=0 = 1|P = t). For any baseline risk other than 0, it can
easily be seen that such values exist, for example if G 6= 0 and H = 0. If the baseline risk
is zero, such values of the parameters also exist, for example if G = 0 and H 6= 0
Baseline risk dependence: Here we define a measure of effect to be baseline risk depen-
dent if, in order for the parameter to stay equal between populations, it is necessary that
the proportion of individuals who respond to treatment (by experiencing the opposite
outcome of what they would have experienced in the absence of treatment) varies with
baseline risk. One can easily observe that COST parameters are not affected by such
baseline risk dependence: This follows almost by definition, since COST parameters were
designed specifically to avoid this form of baseline risk dependence.
Collapsibility: G is collapsible if, for any baseline covariates V , there exist weights Wv
such that G =
∑
Gv∗Wv∑
Wv
. The weights Wv =Pr(V = v|Y
a=0 = 1) always satisfy this
equation; the proof of this is exactly analogous to the corresponding proof for the risk
ratio [[6]]. Analogously, the weights for H are Pr(V = v|Y a=0 = 0), the weights for I are
Pr(V = v|Y a=1 = 1) and the weights for J are Pr(V = v|Y a=1 = 0).
Symmetry: If the coding of the outcome variable is reversed, the only consequence is
that H and G change value. To illustrate this, we will discuss variables and parameters
that are defined according to the recoded outcome; these are denoted with a star (i.e.
Y∗ = (1 − Y )). Recall that we defined G = Pr(Y
a=1 = 1|Y a=0 = 1). If we reverse the
coding, G∗ = Pr(Y
a=1
∗ = 1|Y
a=0
∗ = 1). By replacing Y∗ with Y , this can be written as
G∗ = Pr(Y
a=1 = 0|Y a=0 = 0), which is equal to H . The same logic can be used to show
that H∗ = G.
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APPENDIX 2: PROOFS OF PROPOSITIONS 1-6
In the following proofs, we will simplify the notation by defining S0 = Pr(Y
a=0 = 1|P = s),
S1 = Pr(Y
a=1 = 1|P = s), T0 = Pr(Y
a=0 = 1|P = t) and T1 = Pr(Y
a=1 = 1|P = t).
Proof of Proposition 1. Note, first, that the risk under no treatment and the risk under
treatment can be rewritten in terms of response types:
S0 = Pr(Y
a=0 = 1, Y a=1 = 1) + Pr(Y a=0 = 1, Y a=1 = 0)
S1 = Pr(Y
a=0 = 1, Y a=1 = 1) + Pr(Y a=0 = 0, Y a=1 = 1)
Moreover, because the response types are mutually exclusive and collectively exhaustive
events, it follows that:
1− S0 = Pr(Y
a=0 = 0, Y a=1 = 0) + Pr(Y a=0 = 0, Y a=1 = 1)
1− S1 = Pr(Y
a=0 = 0, Y a=1 = 0) + Pr(Y a=0 = 1, Y a=1 = 0)
Recall that G and H can equivalently be defined as follows:
G =
Pr(Y a=0 = 1, Y a=1 = 1)
Pr(Y a=0 = 1, Y a=1 = 1) + Pr(Y a=0 = 1, Y a=1 = 0)
H =
Pr(Y a=0 = 0, Y a=1 = 0)
Pr(Y a=0 = 0, Y a=1 = 0) + Pr(Y a=0 = 0, Y a=1 = 1)
Therefore, under our definitions of G and H, the following relationship holds in any
population:
S1 = S0 ×Gs + (1− S0)× (1−Hs).
Next, if treatment is monotonically protective, Hs = 1. The second term is therefore
equal to 0, and it follows that S1 = S0 ×Gs , and that Gs =
S1
S0
= RR(−)s.
Proof of Proposition 2.
T1 = T0 ×Gt + (1− T0)× (1−Ht) By same logic as in proposition 1
= T0 ×Gt By monotonicity
= T0 ×Gs By equal treatment effects
T1
T0
= Gs =
S1
S0
By proposition 1
(1)
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Proof of Proposition 3. Define F as T0
S0
. Then, F > 1 if the baseline risk is higher in the
target population, and F < 1 if the baseline risk is lower in the target population. As
in the motivating example, our goal is to estimate T1 from information on T0, S1 and S0.
Let Tˆ1 be the estimate of T1. For a protective treatment, if Tˆ1 < T1, we can conclude that
the prediction is biased away from the null. Our goal is to show that, if the risk ratio
is used to transport the effect, and the effects are equal according to Definition 3, then
Tˆ1 < T1 if F < 1. If the treatment effects H and G are equal between populations s and
t , we know that the following relationship holds:
T1 = G× T0 + (1−H)× (1− T0)
Alternatively, this can be written in terms of S0 and F :
T1 = G× S0 × F + (1−H)× (1− S0 × F )
The risk ratio RR(−) that will be estimated in population s can be written as
RR(−) =
S1
S0
=
G× S0 + (1−H)× (1− S0)
S0
If we use an approach based on assuming that the risk ratio is equal between the popu-
lations, we will estimate T1 by Tˆ1 as follows
Tˆ1 = T0×RR(−) = T0×
G× S0 + (1−H)× (1− S0)
S0
= F × [G×S0+(1−H)× (1−S0)]
We will now compare Tˆ1 with T1 to see which is greater.
T1 = G× S0 × F + (1−H)× (1− S0 × F ) = GFS0 + 1−H − FS0 + HFS0
Tˆ1 = F × [G× S0 + (1−H)× (1− S0)] = GFS0 + F − FS0 − FH + HFS0
Between these two expressions, the terms GFS0, −FS0 and HFS0 and are shared and
cancel. We therefore know that
Tˆ1 < T1 if F − FH < 1−H
or, equivalently,
Tˆ1 < T1 if F (1−H) < 1−H
If H is positive, Tˆ1 < T1 if F < 1
From the preceding results, we can further derive the bias term Tˆ1−T1 = F−FH−1+H ,
which can be used to graph the amount of bias as a function of the ratio of baseline risks
and of the extent of non-monotonicity.
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Proof of Proposition 4. As discussed earlier, we know that S1 = S0×GS +(1−S0)× (1−
Hs). If treatment monotonically increases the incidence, Gs = 1. We therefore have that
S1 = S0 + (1− S0)× (1−Hs). Solving this for Hs, we get
Hs = 1−
S1 − S0
1− S0
=
1− S0 − S1 + S0
1− S0
=
1− S1
1− S0
= RR(+)
(2)
Proof of Proposition 5.
Ht =
1− T1
1− T0
Same logic as in Proposition 4
Hs =
1− T1
1− T0
Equal treatment effects
Hs =
1− S1
1− S0
Proposition 4
1− S1
1− S0
=
1− T1
1− T0
(3)
Proof of Proposition 6. The logic of the proof of Proposition 6 is exactly analogous to
that presented in the context of Proposition 3.
APPENDIX 3
Consider an unmeasured attribute X that interacts with A to determine treatment re-
sponse. We will here outline how background biological knowledge can be encoded as
restrictions on the joint distribution of counterfactuals of the type Y a,x, and show that
these restrictions may have implications for effect equality. This will allow us to clarify
the link between biology and model choice. For simplicity, we will first consider a situ-
ation where response to treatment is fully determined by X; and later outline how this
assumption can be relaxed.
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For illustration, we will consider an example concerning the effect of treatment with
antibiotics (A), on mortality (Y ). We will suppose that response to treatment is fully
determined by bacterial susceptibility to that antibiotic (X). In the following, we will
suppose that attribute X has the same prevalence in populations s and t (for example
because the two populations share the same bacterial gene pool) and that treatment with
A has no effect in the absence of X. Further, suppose that this attribute is independent
of the baseline risk of the outcome (for example, old people at high risk of death may
have the same strains of the bacteria as young people at low risk).
In order to get equality of effects between populations s and t, we need one further
condition: If the attribute X has no effect on Y in the absence of A but prevents Y
in the presence of A, the effect of introducing treatment will be equal between the two
populations; whereas if X has no effect on Y in the presence of A but causes Y in the
absence of A, the two populations will have equality of the effect of removing treatment.
The above is formalized with the following conditions:
1. X is equally distributed in populations s and t: X ⊥ P
2. A has no effect in the absence of X: Y a=0,x=0 = Y a=1,x=0 in all individuals
3. (a) X has no effect in the absence of A: Y a=0,x=0 = Y a=0,x=1 in all individuals
(b) X prevents the outcome in the presence of A: Y a=1,x=1 = 0 in all individuals
(c) X is independent of the baseline risk: X ⊥ Y a=0|P
4. (a) X has no effect in the presence of A: Y a=1,x=0 = Y a=1,x=1 in all individuals
(b) X causes the outcome in the absence of A: Y a=0,x=1 = 1 in all individuals
(c) X is independent of the risk under treatment: X ⊥ Y a=1|P
Proposition 7. If conditions 1, 2 and 3(a-c) hold, then G is equal between populations
s and t. If conditions 1,2 and 4(a-c) hold, then J is equal between the populations.
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Proof of Proposition 7.
Gs = Pr(Y
a=1 = 1|Y a=0 = 1, P = s)
= Pr(Y a=1 = 1|Y a=0 = 1, P = s, X = 0)× Pr(X = 0|Y a=0 = 1, P = s)
+ Pr(Y a=1 = 1|Y a=0 = 1, P = s, X = 1)× Pr(X = 1|Y a=0 = 1, P = s) (Law of total probability)
= Pr(Y a=1,x=0 = 1|Y a=0,x=0 = 1, P = s, X = 0)× Pr(X = 0|Y a=0 = 1, P = s)
+ Pr(Y a=1,x=1 = 1|Y a=0,x=1 = 1, P = s, X = 1)× Pr(X = 1|Y a=0 = 1, P = s) (Consistency)
= Pr(Y a=1,x=0 = 1|Y a=0,x=0 = 1, P = s, X = 0)× Pr(X = 0|Y a=0 = 1, P = s)
+ Pr(Y a=1,x=1 = 1|Y a=0,x=0 = 1, P = s, X = 1)× Pr(X = 1|Y a=0 = 1, P = s) (Assumption 3a)
= Pr(Y a=1,x=0 = 1|Y a=1,x=0 = 1, P = s, X = 0)× Pr(X = 0|Y a=0 = 1, P = s)
+ Pr(Y a=1,x=1 = 1|Y a=1,x=0 = 1, P = s, X = 1)× Pr(X = 1|Y a=0 = 1, P = s) (Assumption 2)
= Pr(X = 0|Y a=0 = 1, P = s) (Assumption 3b)
= Pr(X = 0|P = s)( Assumption 3c)
(4)
With the same argument, we can show that Gt = P r(X = 0|P = t). By assumption 1,
Pr(X = 0|P = s) and Pr(X = 0|P = t) are equal.
Results similar to proposition 7 can be shown for attributes Z that are associated with
a harmful effect of treatment. This will require conditions for Z that are comparable to
3(a-c), and 4(a-c). We will refer to the conditions that lead to equality of the H parameter
as 5(a-c), and the conditions that lead to equality of the I parameter as 6(a-c):
5. (a) Z has no effect in the absence of A: Y a=0,z=0 = Y a=0,z=1 in all individuals
(b) Z causes the outcome in the presence of A: Za=1,z=1 = 1 in all individuals
(c) Z is independent of the baseline risk: Z ⊥ Y a=0|P
6. (a) Z has no effect in the presence of A: Y a=1,z=0 = Y a=1,z=1 in all individuals
(b) Z prevents the outcome in the absence of A: Y a=0,z=1 = 0 in all individuals
(c) Z is independent of the risk under treatment: Z ⊥ Y a=1|P
19
We now sketch the outline of an argument for how this extends to situations where there is
both a protective and a harmful attribute, which together completely determine whether
drug A has an effect. Consider the joint counterfactual Y a,x,z where X is an attribute that
is associated with a protective effect of treatment with A, and Z is an attribute associated
with a harmful effect of treatment with A, and the joint distribution of X and Z is equal
between the populations. It will be necessary that the two attributes are coherent with
each other, in the sense that either X meets conditions 3(a-c) and Z meets conditions
5(a-c), or that X meets conditions 4(a-c) and Z meets conditions 6(a-c).
Suppose that for any combination of X and Z, treatment with A is either ineffective,
protective or harmful. For example, an individual may have a strain of the bacterium
that is susceptible to treatment (X = 1) , but also have a genetic variant that causes a
severe, deadly allergic reaction to the drug (Z = 1). In this case, we may believe that
the allergic reaction supersedes the bacterial susceptibility, i.e. that treatment with A is
harmful for this combination of X and Z.
For any individual, define U = 0 if the person belongs to a joint stratum of X and Z
such that treatment has no effect (i.e. Y a=1,x,z = Y a=0,x,z in all individuals), U = 1 if the
individual belongs to a joint stratum of X and Z such that Y a=1,x,z = 0 in all individuals,
and U = 2 if he belongs to a joint stratum of x,z such that Y a=1,x,z = 1. Because no
combination of X and Y is associated with both harmful and preventative effects of A,
this covers all possibilities.
Using logic similar to the proof for singular attributes, we can show that G is equal to
Pr(U = 1), H is equal to Pr(U = 2), and that these are equal between the two populations.
This can further be extended to multifactorial attributes. Consider the joint counterfac-
tual Y a,x,z where X is a vector of attributes associated with protective effect of treat-
ment, and Z is a vector of attributes associated with a harmful effect of treatment. We
will suppose that all attributes in X either operate according to conditions 3(a-c) or
conditions 4(a-c), and that all attributes in Z operate according to corresponding condi-
tions 5(a-c) or (6a-c) such that the conditions for Z are coherent with the conditions for
X, asdiscussedabove.. This extension will require that for any combination of x and z,
treatment with A is either harmful, protective or without effect; if this is believed to be
the case, individuals can be assigned to strata of U using the same logic as before.
APPENDIX 4
Proposition 8. If the outcome is rare and if RR(+) is equal between two populations,
then the risk difference is approximately equal between the two populations.
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Proof of Proposition 8.
If RR(+) is equal between the two populations, the following relationship holds:
1− Pr(Y a=1|P = s)
1− Pr(Y a=0|P = s)
=
1− Pr(Y a=1 = 1|P = t)
1− Pr(Y a=0 = 1|P = t)
This can be rewritten as:
1− Pr(Y a=1|P = s)− Pr(Y a=0 = 1|P = t) + Pr(Y a=0 = 1|P = t)× Pr(Y a=1|P = s)
= 1− Pr(Y a=1|P = t)− Pr(Y a=0 = 1|P = s) + Pr(Y a=0 = 1|P = s)× Pr(Y a=1|P = t)
If the outcome is rare, the product terms on both sides are close to zero:
1− Pr(Y a=1|P = s)− Pr(Y a=0 = 1|P = t) = 1− Pr(Y a=1|P = t)− Pr(Y a=0 = 1|P = s)
This can be rewritten as:
Pr(Y a=1|P = s)− Pr(Y a=0 = 1|P = s) = Pr(Y a=1|P = t)− Pr(Y a=0 = 1|P = t)
The left side of this expression is RD in population s and the right side is RD in population p:
RDs = RDt
(5)
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